Y-mAbs Therapeutics (NASDAQ:YMAB) said it has received FDA clearance to begin Phase 1 testing of its radioimmunotherapy candidate CD38-SADA in the treatment of relapsed or refractory non-Hodgkin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback